Rogaine efficacy study in non-Caucasian women suggested by advisory cmte..
This article was originally published in The Tan Sheet
Executive Summary
ROGAINE PHASE IV EFFICACY STUDY IN NON-CAUCASIAN WOMEN SUGGESTED by members of the Nonprescription Drugs, Dermatologic and Ophthalmic Drugs Advisory Committees at a Nov. 17 joint meeting. Dermatologic committee member Denise Buntin, MD, Vanderbilt University Medical Center, pointed out that Pharmacia & Upjohn did not submit much data on the use of Rogaine (2%) minoxidil hair regrowth treatment for androgenetic alopecia, or hereditary baldness, in non-Caucasian women.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: